Investor Presentation
Commercial
execution
18
Investor presentation
First six months of 2022
Strategic aspirations 2025
Purpose and
sustainability
(ESG)
•
Progress towards zero environmental impact
Being respected for adding value to society
Being recognised as a sustainable employer
Strengthen Diabetes leadership - aim at global value
market share of more than 1/3
More than 25 billion DKK in Obesity sales by 2025
Secure a sustained growth outlook for Rare disease
Financials
Innovation and
therapeutic focus
.
•
•
Further raise the innovation-bar for diabetes treatment
Develop a leading portfolio of superior treatment
solutions for obesity
Strengthen and progress the Rare disease pipeline
Establish presence in Other serious chronic diseases
focusing on CVD, NASH and CKD
Deliver solid sales and operating profit growth
•
Deliver 6-10% sales growth in IO
•
Transform 70% of sales in the US¹
1 From 2015 to 2022, 70% of sales to come from products launched from 2015. IO: International Operations; CVD: Cardiovascular disease; NASH: Non-alcoholic steatohepatitis; CKD: Chronic kidney disease.
Note: The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth.
Drive operational efficiencies across the value chain to
enable investments in future growth assets
Deliver free cash flow to enable attractive capital
allocation to shareholders
Novo NordiskⓇView entire presentation